MA54411B1 - Compositions contenant de l'ibrutinib - Google Patents

Compositions contenant de l'ibrutinib

Info

Publication number
MA54411B1
MA54411B1 MA54411A MA54411A MA54411B1 MA 54411 B1 MA54411 B1 MA 54411B1 MA 54411 A MA54411 A MA 54411A MA 54411 A MA54411 A MA 54411A MA 54411 B1 MA54411 B1 MA 54411B1
Authority
MA
Morocco
Prior art keywords
sodium
lymphoma
compositions
ibrutinib
metabolite
Prior art date
Application number
MA54411A
Other languages
English (en)
Other versions
MA54411A (fr
Inventor
Dilip Gole
Manish Kumar Gupta
Kaustubh Tambwekar
Binuraj Krishnan Nair
Maristella Bernini
Sabine Inghelbrecht
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54411(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA54411A publication Critical patent/MA54411A/fr
Publication of MA54411B1 publication Critical patent/MA54411B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques contenant de l'ibrutinib et des procédés pour les préparer. Les compositions peuvent être utilisées dans le traitement de diverses affections comprenant, sans limitation, les troubles prolifératifs des cellules b tels que le lymphome non hodgkinien (lymphome diffus à grandes cellules b, lymphome folliculaire, lymphome à cellules du manteau ou lymphome de burkitt), la macroglobulinémie de waldenström, myélome plasmocytaire, leucémie lymphoïde chronique, lymphome ou leucémie. Ces compositions sont conçues pour une ingestion orale. Les compositions sont contenues dans une capsule telle qu'un standard ou un spray ou dans une formulation liquide telle qu'une suspension. Dans un mode de réalisation, la composition pharmaceutique contient de l'ibrutinib, un sel, un promédicament ou un métabolite de celui-ci, de la cellulose microcristalline, de la croscarmellose sodique, du laurylsulfate de sodium et du stéarate de magnésium. Dans un autre mode de réalisation, la composition pharmaceutique contient de l'ibrutinib, un sel, un promédicament ou un métabolite de celui-ci, de la cellulose microcristalline, de la carboxyméthylcellulose sodique, de l'hydroxypropylméthylcellulose, de l'acide citrique monohydraté, de l'hydrogénophosphate disodique, du sucralose, du parahydroxybenzoate de méthyle de sodium, du parahydroxybenzoate d'éthyle de sodium, de l'acide chlorhydrique concentré, du sodium. Hydroxyde et eau.
MA54411A 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib MA54411B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06

Publications (2)

Publication Number Publication Date
MA54411A MA54411A (fr) 2021-10-13
MA54411B1 true MA54411B1 (fr) 2023-11-30

Family

ID=55806788

Family Applications (2)

Application Number Title Priority Date Filing Date
MA041901A MA41901A (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib
MA54411A MA54411B1 (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA041901A MA41901A (fr) 2015-04-06 2016-04-06 Compositions contenant de l'ibrutinib

Country Status (28)

Country Link
US (5) US20160287594A1 (fr)
EP (3) EP3892302B8 (fr)
JP (3) JP2018513852A (fr)
KR (2) KR20240013859A (fr)
CN (2) CN113546054A (fr)
AU (3) AU2016246669B2 (fr)
CA (1) CA2981601A1 (fr)
CL (1) CL2017002512A1 (fr)
DK (1) DK3892302T3 (fr)
EA (1) EA033992B1 (fr)
ES (1) ES2964472T3 (fr)
FI (1) FI3892302T3 (fr)
HK (1) HK1250925A1 (fr)
HR (1) HRP20231207T1 (fr)
HU (1) HUE063751T2 (fr)
IL (2) IL295941A (fr)
LT (1) LT3892302T (fr)
MA (2) MA41901A (fr)
MD (1) MD3892302T2 (fr)
MX (2) MX2017012822A (fr)
PH (1) PH12017501811A1 (fr)
PL (1) PL3892302T3 (fr)
PT (1) PT3892302T (fr)
RS (1) RS64653B1 (fr)
SG (2) SG10202103458QA (fr)
SI (1) SI3892302T1 (fr)
UA (1) UA125681C2 (fr)
WO (1) WO2016164404A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190040370A (ko) 2012-06-04 2019-04-17 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
WO2018167628A1 (fr) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Composition pharmaceutique de suspension orale d'agents immunosuppresseurs
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
EP3668508A1 (fr) 2017-08-19 2020-06-24 FTF Pharma Private Limited Composition pharmaceutique orale comprenant du zonisamide et son procédé de préparation
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
CA3089537A1 (fr) * 2018-01-20 2019-07-25 Natco Pharma Limited Compositions pharmaceutiques comprenant de l'ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
CA3100146A1 (fr) * 2018-06-15 2019-12-19 Janssen Pharmaceutica Nv Formulations/compositions comprenant de l'ibrutinib
WO2020039263A2 (fr) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Suspension pharmaceutique pour forme galénique orale
US12083222B2 (en) 2018-08-18 2024-09-10 Oncosol Limited Chemotherapeutic pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
US20200171034A1 (en) * 2018-11-30 2020-06-04 Janssen Biotech, Inc. Methods Of Treating Follicular Lymphoma
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
WO2022260667A1 (fr) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Formes posologiques orales d'ibrutinib
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013467A (es) * 2005-04-28 2008-01-21 Wyeth Corp Tanaproget micronizado y composiciones que contienen el mismo.
EP2201840B1 (fr) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de Bruton
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
CA3113343A1 (fr) 2010-06-03 2011-12-08 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
MX361772B (es) 2011-10-19 2018-12-17 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
KR20190040370A (ko) * 2012-06-04 2019-04-17 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
US20150140085A1 (en) * 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
EP3603715B1 (fr) 2013-03-14 2021-03-03 Fisher & Paykel Healthcare Limited Support de cathéter ayant un orifice d'aspiration
CA2920821A1 (fr) * 2013-08-12 2015-02-19 The Yokohama Rubber Co., Ltd. Composition d'appret
ES2709509T3 (es) * 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
WO2015071432A1 (fr) 2013-11-14 2015-05-21 Sandoz Ag Compositions pharmaceutiques à base d'ibrutinib
JP2017523206A (ja) 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor

Also Published As

Publication number Publication date
SG11201707989PA (en) 2017-10-30
MX2017012822A (es) 2018-06-13
MA54411A (fr) 2021-10-13
IL254695A0 (en) 2017-11-30
EP3892302A1 (fr) 2021-10-13
EP3892302B8 (fr) 2023-10-18
FI3892302T3 (fi) 2023-11-03
US20230263804A1 (en) 2023-08-24
KR102632745B1 (ko) 2024-02-01
US20160287594A1 (en) 2016-10-06
EP3892302B1 (fr) 2023-09-06
JP2018513852A (ja) 2018-05-31
US20200171036A1 (en) 2020-06-04
AU2016246669B2 (en) 2021-07-15
PL3892302T3 (pl) 2024-03-11
AU2021250925A1 (en) 2021-11-11
SG10202103458QA (en) 2021-05-28
UA125681C2 (uk) 2022-05-18
CL2017002512A1 (es) 2018-03-16
AU2016246669A1 (en) 2017-10-12
AU2021250925B2 (en) 2023-11-16
CA2981601A1 (fr) 2016-10-13
US20220211713A1 (en) 2022-07-07
JP2022031690A (ja) 2022-02-22
MD3892302T2 (ro) 2024-03-31
EA033992B1 (ru) 2019-12-17
EP3280446A1 (fr) 2018-02-14
PT3892302T (pt) 2023-11-15
MX2021015250A (es) 2022-01-24
ES2964472T3 (es) 2024-04-08
BR112017021325A2 (pt) 2018-06-26
LT3892302T (lt) 2023-11-10
WO2016164404A1 (fr) 2016-10-13
US20170252344A1 (en) 2017-09-07
JP2024026087A (ja) 2024-02-28
CN107530293A (zh) 2018-01-02
IL254695B2 (en) 2023-02-01
SI3892302T1 (sl) 2023-11-30
KR20170134582A (ko) 2017-12-06
MA41901A (fr) 2021-04-14
EA201792224A1 (ru) 2018-06-29
EP4272835A2 (fr) 2023-11-08
IL254695B (en) 2022-10-01
JP7438178B2 (ja) 2024-02-26
AU2024200883A1 (en) 2024-02-29
CN113546054A (zh) 2021-10-26
HK1250925A1 (zh) 2019-01-18
EP4272835A3 (fr) 2023-12-20
RS64653B1 (sr) 2023-10-31
HRP20231207T1 (hr) 2024-01-19
KR20240013859A (ko) 2024-01-30
IL295941A (en) 2022-10-01
DK3892302T3 (da) 2023-11-13
HUE063751T2 (hu) 2024-01-28
PH12017501811A1 (en) 2018-04-23

Similar Documents

Publication Publication Date Title
MA54411B1 (fr) Compositions contenant de l'ibrutinib
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA37610B1 (fr) Formulations de testostérone proliposomales
MA42292A (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA32692B1 (fr) Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin
JP2018513852A5 (fr)
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA38399A1 (fr) Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique
MA30807B1 (fr) Compositions pharmaceutiques.
MA44206A (fr) Comprimé orodispersible comprenant estetrol
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
WO2016210003A3 (fr) Compositions orales contenant un ester de 17-hydroxyprogestérone et procédés s'y rapportant
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2010007281A (es) Composiciones farmaceuticas de amlodipina y valsartan.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
MA35088B1 (fr) Formulation comprenant un dérivé de phénylaminopyrimidine en tant qu'agent actif